rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-145-153rsp-3543Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESОбзор рекомендаций 2022 Американской коллегии ревматологов (ACR) по профилактике и лечению глюкокортикоидного остеопороза: что нового?Review of 2022 American College of Rheumatology (ACR) guideline for the prevention and treatment of glucocorticoid-induced osteoporosis: what’s new?https://orcid.org/0000-0003-4739-4302ТоропцоваН. В.ToroptsovaN. V.

Торопцова Наталья Владимировна

115522, Москва, Каширское шоссе, 34а

Natalia Toroptsova

115522, Moscow, Kashirskoye Highway, 34A

torop@irramn.ruhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а;

119991, Москва, ул. Трубецкая, 8, стр. 2

 Evgeny L. Nasonov

115522,  Moscow, Kashirskoye Highway, 34A;

119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202428042024622145153Copyright © Торопцова Н.В., Насонов Е.Л., 20242024Торопцова Н.В., Насонов Е.Л.Toroptsova N.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3543

Глюкокортикоиды (ГК) применяются в медицине с середины ХХ века, в том числе для лечения различных системных ревматических заболеваний. Однако длительный прием ГК может сопровождаться развитием серьезных неблагоприятных реакций, одной из которых является вторичный остеопороз, приводящий к возникновению низкоэнергетических переломов, что отражается на качестве жизни больных и может вести к увеличению риска смерти. В статье представлен обзор с обсуждением новой редакции клинических рекомендаций Американской коллегии ревматологов 2022 года по профилактике и лечению глюкокортикоидного остеопороза у взрослых пациентов.

Glucocorticoids (GC) have been used in medicine since the middle of the twentieth century, including for the treatment of various systemic rheumatic diseases. However, long-term use of GC may be accompanied by the development of serious complications, one of which is secondary osteoporosis, leading to low-energy fractures, which affects the quality of life of patients and may lead to an increased risk of death. This article presents an overview with a discussion of the new edition of the guideline of the American College of Rheumatology (ACR) 2022 for the prevention and treatment of glucocorticoid-induced osteoporosis in adult patients.

глюкокортикоидыглюкокортикоидный остеопорозриск переломовлечение остеопорозаклинические рекомендацииglucocorticoidsglucocorticoid-induced osteoporosisfracture riskosteoporosis treatmentguidelineReferencesMichaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):885-906. doi: 10.1016/j.berh.2007.06.002Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):885-906. doi: 10.1016/j.berh.2007.06.002Баранова ИА, Ершова ОБ, Анаев ЭХ, Анохина ТН, Аношенкова ОН, Батын СЗ, и др. Оценка частоты и факторов риска низкоэнергетических переломов скелета по данным опроса больных хроническими воспалительными заболеваниями. Результаты многоцентрового исследования российской ассоциации по остеопорозу ГЛЮКОСТ. Остеопороз и остеопатии. 2014;17(3):9-14. doi: 10.14341/osteo201439-14Baranova IA, Ershova OB, Anaev EKh, Anikhina TN, Anoshenkova ON, Batyn SZ, et al. Prevalence and risk factors of low-energy skeletal fractures in patients with chronic inflammatory diseases. The results of a multicenter study of the Russian Association on Osteoporosis GLUKOST. Osteoporosis and Bone Diseases. 2014;17(3):9-14 (In Russ.)Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383- 1389. doi: 10.1093/rheumatology/39.12.1383Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383- 1389. doi: 10.1093/rheumatology/39.12.1383De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208-214. doi: 10.1002/art.22294De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208-214. doi: 10.1002/art.22294Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int. 2011; 22:809-816. doi: 10.1007/s00198-010-1524-7Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis Int. 2011; 22:809-816. doi: 10.1007/s00198-010-1524-7Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi: 10.1002/acr.25240Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi: 10.1002/acr.25240Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726-735. doi: 10.1016/j.jclinepi.2013.02.003Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726-735. doi: 10.1016/j.jclinepi.2013.02.003Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi: 10.1136/bmj.39489.470347.ADGuyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi: 10.1136/bmj.39489.470347.ADRoss AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58. doi: 10.1210/jc.2010-2704Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58. doi: 10.1210/jc.2010-2704Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis [review]. Cochrane Database Syst Rev. 2016;10:CD001347. doi: 10.1002/14651858.CD001347.pub2Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis [review]. Cochrane Database Syst Rev. 2016;10:CD001347. doi: 10.1002/14651858.CD001347.pub2Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039. doi: 10.1056/NEJMoa071408Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039. doi: 10.1056/NEJMoa071408Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724-738. doi: 10.20945/2359-3997000000564Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724-738. doi: 10.20945/2359-3997000000564Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253- 1263. doi: 10.1016/S0140-6736(09)60250-6Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253- 1263. doi: 10.1016/S0140-6736(09)60250-6Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoidinduced osteoporosis: A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoidinduced osteoporosis: A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. doi: 10.1002/art.24879Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. doi: 10.1002/art.24879Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68-73. doi: 10.1002/(SICI)1096-9926(199908)60:23.0.CO;2-HPatlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60(2):68-73. doi: 10.1002/(SICI)1096-9926(199908)60:23.0.CO;2-HMoe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al.; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi: 10.1038/sj.ki.5000414Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al.; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi: 10.1038/sj.ki.5000414Hiramatsu R, Ubara Y, Sawa N, Sakai A. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant. 2021;36:1900-1907. doi: 10.1093/ndt/gfaa359Hiramatsu R, Ubara Y, Sawa N, Sakai A. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant. 2021;36:1900-1907. doi: 10.1093/ndt/gfaa359Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al.; EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852-860. doi: 10.1210/jc.2007-0711Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al.; EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93(3):852-860. doi: 10.1210/jc.2007-0711Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013;28(6):1328-1336. doi: 10.1002/jbmr.1853Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013;28(6):1328-1336. doi: 10.1002/jbmr.1853Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751. doi: 10.1359/JBMR.040117Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751. doi: 10.1359/JBMR.040117Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-1155. doi: 10.1016/S0140-6736(15)61120-5Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-1155. doi: 10.1016/S0140-6736(15)61120-5Cosman F. Anabolic and antiresorptive therapy for osteoporosis: Combination and sequential approaches. Curr Osteoporos Rep. 2014;12:385-395. doi: 10.1007/s11914-014-0237-9Cosman F. Anabolic and antiresorptive therapy for osteoporosis: Combination and sequential approaches. Curr Osteoporos Rep. 2014;12:385-395. doi: 10.1007/s11914-014-0237-9Cosman F, Huang S, McDermott M, Cummings SR. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res. 2022;37(11):2112-2120. doi: 10.1002/jbmr.4705Cosman F, Huang S, McDermott M, Cummings SR. Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res. 2022;37(11):2112-2120. doi: 10.1002/jbmr.4705Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi: 10.1210/jc.2019-00221Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. doi: 10.1210/jc.2019-00221Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2020;105(3):e255-e264. doi: 10.1210/clinem/dgz095Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, et al. Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab. 2020;105(3):e255-e264. doi: 10.1210/clinem/dgz095Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: A retrospective study. Osteoporos Int. 2023;34(3):573-584. doi: 10.1007/s00198-022-06648-9Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: A retrospective study. Osteoporos Int. 2023;34(3):573-584. doi: 10.1007/s00198-022-06648-9Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide follow-up study (DATA-Follow-up). Bone. 2017;98:54-58. doi: 10.1016/j.bone.2017.03.006Leder BZ, Tsai JN, Jiang LA, Lee H. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide follow-up study (DATA-Follow-up). Bone. 2017;98:54-58. doi: 10.1016/j.bone.2017.03.006Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, et al. Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int. 2022;33(6):1243-1256. doi: 10.1007/s00198-021-06174-0Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, et al. Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int. 2022;33(6):1243-1256. doi: 10.1007/s00198-021-06174-0Solling AS, Harslof T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: A 2-year randomized study. J Bone Miner Res. 2021;36:1245-1254. doi: 10.1002/jbmr.4305.Solling AS, Harslof T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: A 2-year randomized study. J Bone Miner Res. 2021;36:1245-1254. doi: 10.1002/jbmr.4305.Napoli N, Langdahl BL, Ljunggren Ö, Lespessailles E, Kapetanos G, Kocjan T, et al. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo® Observational Study (ExFOS). Calcif Tissue Int. 2018;103(4):359-371. doi: 10.1007/s00223-018-0437-xNapoli N, Langdahl BL, Ljunggren Ö, Lespessailles E, Kapetanos G, Kocjan T, et al. Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo® Observational Study (ExFOS). Calcif Tissue Int. 2018;103(4):359-371. doi: 10.1007/s00223-018-0437-xAmiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: A network meta-analysis. Osteoporos Int. 2016;27(6):1989-1998. doi: 10.1007/s00198-015-3476-4Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: A network meta-analysis. Osteoporos Int. 2016;27(6):1989-1998. doi: 10.1007/s00198-015-3476-4Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl 2):407-413. doi: 10.1007/s00198-010-1253-yKanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F. Development and use of FRAX® in osteoporosis. Osteoporos Int. 2010;21(Suppl 2):407-413. doi: 10.1007/s00198-010-1253-yde Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589-602. doi: 10.1007/s00198-004-1614-5de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: A review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589-602. doi: 10.1007/s00198-004-1614-5Белая ЖЕ, Белова КЮ, Бирюкова ЕВ, Дедов ИИ, Дзеранова ЛК, Драпкина ОМ, и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4-47. doi: 10.14341/osteo12930Belaya ZhE, Belova KYu, Biryukova EV, Dedov II, Dzeranova LK, Drapkina OM, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47 (In Russ.)Лесняк ОМ (ред.). Остеопороз; 2-е издание, переработанное и дополненное. М.:ГЭОТАР-Медиа;2023.Lesnyak OM (ed.). Osteoporosis; 2nd edition, revised and expanded. Moscow:GEOTAR-Media;2023 (In Russ.)

The authors declare that there are no conflicts of interest present.